Sectors
CMPX
Compass Therapeutics, Inc.
2.09
76 x 2.09
121 x 2.10
bid
ask
+
0.10
5.03%
11:22 AM
timesize
| Ytd | -61.08% | |
| 1y | -24.82% |
2.03
day range
2.10
1.61
52 week range
6.88
| Open | 2.05 | Prev Close | 1.99 | Low | 2.03 | High | 2.10 | Mkt Cap | 358.38M |
| Vol | 1.29M | Avg Vol | 3.73M | EPS | -0.40 | P/E | -4.97 | Forward P/E | -10.86 |
| Beta | 0.92 | Short Ratio | 12.39 | Inst. Own | 88.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.11 | 200-d Avg | 4.18 | 1yr Est | 13.64 |
| Income Statement | |||
| Operating Expenses | 20.30M | ||
| Research and Development Expense | 13.39M | ||
| Selling, General and Administrative Expense | 6.91M | ||
| Operating Income | -20.30M | ||
| Net Income | -18.32M | ||
| Net Income Common Stock | -18.32M | ||
| Net Income Common Stock (USD) | -18.32M | ||
| Consolidated Income | -18.32M | ||
| Earnings per Basic Share | -0.10 | ||
| Earnings per Basic Share (USD) | -0.10 | ||
| Earnings per Diluted Share | -0.10 | ||
| Earning Before Interest & Taxes (EBIT) | -18.32M | ||
| Earning Before Interest & Taxes (USD) | -18.32M | ||
| Weighted Average Shares | 186.40M | ||
| Weighted Average Shares Diluted | 186.40M | ||
| Balance Sheet | |||
| Cash and Equivalents | 55.74M | ||
| Cash and Equivalents (USD) | 55.74M | ||
| Investments | 139.52M | ||
| Investments Current | 139.52M | ||
| Current Assets | 195.69M | ||
| Property, Plant & Equipment Net | 8.91M | ||
| Total Assets | 205.17M | ||
| Debt Current | 1.37M | ||
| Total Debt | 9.79M | ||
| Current Liabilities | 10.28M | ||
| Debt Non-Current | 8.42M | ||
| Total Liabilities | 18.70M | ||
| Accumulated Retained Earnings (Deficit) | -449.49M | ||
| Accumulated Other Comprehensive Income | -159.00K | ||
| Shareholders Equity | 186.47M | ||
| Shareholders Equity (USD) | 186.47M | ||
| Assets Non-Current | 9.48M | ||
| Total Debt (USD) | 9.79M | ||
| Liabilities Non-Current | 8.42M | ||
| Trade and Non-Trade Payables | 906.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 368.00K | ||
| Net Cash Flow from Financing | 3.37M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 24.53M | ||
| Capital Expenditure | -82.00K | ||
| Issuance (Purchase) of Equity Shares | 3.85M | ||
| Net Cash Flow from Investing | 38.43M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 38.51M | ||
| Net Cash Flow from Operations | -17.27M | ||
| Share Based Compensation | 5.07M | ||